Remaining the industry’s leading forum for cell therapy analytical professionals, the 7th Cell Therapy Analytical Development Summit returned in 2025 to aid you in demonstrating product safety, functionality, and quality before heading to market.

Covering early- to late-stage assay development, this year's meeting offered focused learning and addressed specific analytical needs across two refined tracks. No matter where attendees stood in the product development cycle, they were able to gain hands-on expertise from designing predictive potency assays, through to validating and transferring methods for late-phase trials.

Featuring first-hand case studies and experiences from Takeda, Bayer, Genentech, Adicet Bio, Quell Therapeutics, and the U.S. Pharmacopeia, seize the opportunity in 2026 to benchmark against peers, exchange solutions to persistent challenges, and strengthen your analytical toolkit, to excel in an increasingly competitive cell therapy landscape.